CA2982775A1 - Methods for typing of lung cancer - Google Patents
Methods for typing of lung cancer Download PDFInfo
- Publication number
- CA2982775A1 CA2982775A1 CA2982775A CA2982775A CA2982775A1 CA 2982775 A1 CA2982775 A1 CA 2982775A1 CA 2982775 A CA2982775 A CA 2982775A CA 2982775 A CA2982775 A CA 2982775A CA 2982775 A1 CA2982775 A1 CA 2982775A1
- Authority
- CA
- Canada
- Prior art keywords
- biomarkers
- sample
- classifier biomarkers
- classifier
- hybridization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 185
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 101
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 89
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 89
- 239000000090 biomarker Substances 0.000 claims abstract description 384
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 61
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 44
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 40
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 40
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 31
- 230000002062 proliferating effect Effects 0.000 claims abstract description 31
- 230000000241 respiratory effect Effects 0.000 claims abstract description 31
- 201000011510 cancer Diseases 0.000 claims abstract description 27
- 201000005249 lung adenocarcinoma Diseases 0.000 claims abstract description 10
- 239000000523 sample Substances 0.000 claims description 303
- 230000014509 gene expression Effects 0.000 claims description 188
- 208000009956 adenocarcinoma Diseases 0.000 claims description 150
- 238000009396 hybridization Methods 0.000 claims description 103
- 230000000955 neuroendocrine Effects 0.000 claims description 100
- 239000002299 complementary DNA Substances 0.000 claims description 78
- 238000012549 training Methods 0.000 claims description 63
- 238000004458 analytical method Methods 0.000 claims description 59
- 210000004072 lung Anatomy 0.000 claims description 48
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 48
- 108020004999 messenger RNA Proteins 0.000 claims description 40
- 238000010240 RT-PCR analysis Methods 0.000 claims description 33
- 230000000877 morphologic effect Effects 0.000 claims description 33
- 230000002441 reversible effect Effects 0.000 claims description 33
- 108091034117 Oligonucleotide Proteins 0.000 claims description 30
- 238000003556 assay Methods 0.000 claims description 29
- 230000004083 survival effect Effects 0.000 claims description 25
- 238000003559 RNA-seq method Methods 0.000 claims description 24
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 24
- 208000000649 small cell carcinoma Diseases 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 208000002458 carcinoid tumor Diseases 0.000 claims description 19
- 230000000295 complement effect Effects 0.000 claims description 14
- 238000012896 Statistical algorithm Methods 0.000 claims description 13
- 239000012188 paraffin wax Substances 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 10
- 238000010195 expression analysis Methods 0.000 claims description 6
- 239000012520 frozen sample Substances 0.000 claims description 3
- 210000005265 lung cell Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 description 140
- 239000013615 primer Substances 0.000 description 84
- 210000004027 cell Anatomy 0.000 description 78
- 108020004635 Complementary DNA Proteins 0.000 description 69
- 238000010804 cDNA synthesis Methods 0.000 description 69
- 210000001519 tissue Anatomy 0.000 description 57
- 102000004169 proteins and genes Human genes 0.000 description 49
- 238000003745 diagnosis Methods 0.000 description 41
- 238000003199 nucleic acid amplification method Methods 0.000 description 32
- 230000003321 amplification Effects 0.000 description 31
- 239000003795 chemical substances by application Substances 0.000 description 26
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 25
- 201000009030 Carcinoma Diseases 0.000 description 24
- 238000004422 calculation algorithm Methods 0.000 description 24
- 239000013074 reference sample Substances 0.000 description 21
- 238000012552 review Methods 0.000 description 20
- 239000004037 angiogenesis inhibitor Substances 0.000 description 19
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 19
- 208000037841 lung tumor Diseases 0.000 description 18
- 230000007170 pathology Effects 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 238000012360 testing method Methods 0.000 description 17
- 230000027455 binding Effects 0.000 description 16
- 238000003752 polymerase chain reaction Methods 0.000 description 16
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 14
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 14
- -1 e.g Proteins 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 14
- 238000002493 microarray Methods 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000001514 detection method Methods 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 11
- 239000005557 antagonist Substances 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 11
- 230000002440 hepatic effect Effects 0.000 description 11
- 238000010606 normalization Methods 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 102100032216 Calcium and integrin-binding protein 1 Human genes 0.000 description 10
- 102000010792 Chromogranin A Human genes 0.000 description 10
- 108010038447 Chromogranin A Proteins 0.000 description 10
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 10
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 230000002962 histologic effect Effects 0.000 description 10
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 9
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 9
- 102100027833 14-3-3 protein sigma Human genes 0.000 description 8
- 102100031323 Anthrax toxin receptor 1 Human genes 0.000 description 8
- 102100032919 Chromobox protein homolog 1 Human genes 0.000 description 8
- 108010009367 Cyclin-Dependent Kinase Inhibitor p18 Proteins 0.000 description 8
- 102100024465 Cyclin-dependent kinase 4 inhibitor C Human genes 0.000 description 8
- 102100037709 Desmocollin-3 Human genes 0.000 description 8
- 102100037832 Docking protein 1 Human genes 0.000 description 8
- 102100039417 Gap junction beta-5 protein Human genes 0.000 description 8
- 102100022123 Hepatocyte nuclear factor 1-beta Human genes 0.000 description 8
- 101000797584 Homo sapiens Chromobox protein homolog 1 Proteins 0.000 description 8
- 101000880960 Homo sapiens Desmocollin-3 Proteins 0.000 description 8
- 101000639987 Homo sapiens Stearoyl-CoA desaturase 5 Proteins 0.000 description 8
- 102100033930 Stearoyl-CoA desaturase 5 Human genes 0.000 description 8
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 238000012706 support-vector machine Methods 0.000 description 8
- 102100028186 ATP-binding cassette sub-family C member 5 Human genes 0.000 description 7
- 101710103933 Calcium and integrin-binding protein 1 Proteins 0.000 description 7
- 102100030549 Cytochrome b5 type B Human genes 0.000 description 7
- 102100037994 E3 ubiquitin-protein ligase MGRN1 Human genes 0.000 description 7
- 102000000802 Galectin 3 Human genes 0.000 description 7
- 108010001517 Galectin 3 Proteins 0.000 description 7
- 102100027893 Homeobox protein Nkx-2.1 Human genes 0.000 description 7
- 101000986622 Homo sapiens ATP-binding cassette sub-family C member 5 Proteins 0.000 description 7
- 101000796095 Homo sapiens Anthrax toxin receptor 1 Proteins 0.000 description 7
- 101000951423 Homo sapiens E3 ubiquitin-protein ligase MGRN1 Proteins 0.000 description 7
- 101001045758 Homo sapiens Hepatocyte nuclear factor 1-beta Proteins 0.000 description 7
- 101000760817 Homo sapiens Macrophage-capping protein Proteins 0.000 description 7
- 101000957741 Homo sapiens Microtubule-associated protein RP/EB family member 3 Proteins 0.000 description 7
- 102100024573 Macrophage-capping protein Human genes 0.000 description 7
- 102100038678 Microtubule-associated protein RP/EB family member 3 Human genes 0.000 description 7
- 102000048850 Neoplasm Genes Human genes 0.000 description 7
- 108700019961 Neoplasm Genes Proteins 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 238000002790 cross-validation Methods 0.000 description 7
- 238000007405 data analysis Methods 0.000 description 7
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- VUFNLQXQSDUXKB-DOFZRALJSA-N 2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]ethyl (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OCCOC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 VUFNLQXQSDUXKB-DOFZRALJSA-N 0.000 description 6
- 108010085238 Actins Proteins 0.000 description 6
- 102000007469 Actins Human genes 0.000 description 6
- 102000014914 Carrier Proteins Human genes 0.000 description 6
- 102100034177 Clathrin coat assembly protein AP180 Human genes 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102100040229 Homeobox protein Hox-D1 Human genes 0.000 description 6
- 101000732333 Homo sapiens Clathrin coat assembly protein AP180 Proteins 0.000 description 6
- 101000726631 Homo sapiens Cytochrome b5 type B Proteins 0.000 description 6
- 101001037162 Homo sapiens Homeobox protein Hox-D1 Proteins 0.000 description 6
- 101001033715 Homo sapiens Insulinoma-associated protein 1 Proteins 0.000 description 6
- 101000757378 Homo sapiens Transcription factor AP-2-alpha Proteins 0.000 description 6
- 102100039091 Insulinoma-associated protein 1 Human genes 0.000 description 6
- 102100039919 Intercellular adhesion molecule 5 Human genes 0.000 description 6
- 102000014150 Interferons Human genes 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 6
- 102000007330 LDL Lipoproteins Human genes 0.000 description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 6
- 102000035195 Peptidases Human genes 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- 102100030264 Pleckstrin Human genes 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 102100022972 Transcription factor AP-2-alpha Human genes 0.000 description 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 6
- 108091008324 binding proteins Proteins 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 6
- 108010018828 cadherin 5 Proteins 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- 210000004153 islets of langerhan Anatomy 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 210000003470 mitochondria Anatomy 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 108010026735 platelet protein P47 Proteins 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 238000004393 prognosis Methods 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 108090000312 Calcium Channels Proteins 0.000 description 5
- 102000003922 Calcium Channels Human genes 0.000 description 5
- 102100027466 Cofilin-1 Human genes 0.000 description 5
- 101710116362 E3 ubiquitin-protein ligase sina Proteins 0.000 description 5
- 102000004150 Flap endonucleases Human genes 0.000 description 5
- 108090000652 Flap endonucleases Proteins 0.000 description 5
- 101000805172 Homo sapiens Docking protein 1 Proteins 0.000 description 5
- 101000584362 Homo sapiens Myosin-binding protein H Proteins 0.000 description 5
- 101001096179 Homo sapiens Pleckstrin homology domain-containing family A member 6 Proteins 0.000 description 5
- 101000666730 Homo sapiens T-complex protein 1 subunit alpha Proteins 0.000 description 5
- 101000626125 Homo sapiens Tetranectin Proteins 0.000 description 5
- 102100030626 Myosin-binding protein H Human genes 0.000 description 5
- 108091008606 PDGF receptors Proteins 0.000 description 5
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 5
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 5
- 108010000605 Ribosomal Proteins Proteins 0.000 description 5
- 102000002278 Ribosomal Proteins Human genes 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 102100038410 T-complex protein 1 subunit alpha Human genes 0.000 description 5
- 102000008790 VE-cadherin Human genes 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 108010023082 activin A Proteins 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 108010044426 integrins Proteins 0.000 description 5
- 102000006495 integrins Human genes 0.000 description 5
- 230000005732 intercellular adhesion Effects 0.000 description 5
- 230000015654 memory Effects 0.000 description 5
- 239000011325 microbead Substances 0.000 description 5
- 108091014719 myosin binding proteins Proteins 0.000 description 5
- 102000025599 myosin binding proteins Human genes 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000003196 serial analysis of gene expression Methods 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 210000001685 thyroid gland Anatomy 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 101150028074 2 gene Proteins 0.000 description 4
- 101150090724 3 gene Proteins 0.000 description 4
- 102100021660 60S ribosomal protein L28 Human genes 0.000 description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 4
- 101150076489 B gene Proteins 0.000 description 4
- 102100029761 Cadherin-5 Human genes 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 4
- 101000827763 Drosophila melanogaster Fibroblast growth factor receptor homolog 1 Proteins 0.000 description 4
- 102100031748 E3 ubiquitin-protein ligase SIAH2 Human genes 0.000 description 4
- 108090000852 Forkhead Transcription Factors Proteins 0.000 description 4
- 102000004315 Forkhead Transcription Factors Human genes 0.000 description 4
- 101000590281 Homo sapiens 26S proteasome non-ATPase regulatory subunit 14 Proteins 0.000 description 4
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 description 4
- 101000968042 Homo sapiens Desmocollin-2 Proteins 0.000 description 4
- 101000707245 Homo sapiens E3 ubiquitin-protein ligase SIAH2 Proteins 0.000 description 4
- 101001024566 Homo sapiens Ecto-ADP-ribosyltransferase 4 Proteins 0.000 description 4
- 101000889145 Homo sapiens Gap junction beta-5 protein Proteins 0.000 description 4
- 101000632178 Homo sapiens Homeobox protein Nkx-2.1 Proteins 0.000 description 4
- 101000962526 Homo sapiens Hyaluronidase-2 Proteins 0.000 description 4
- 101000984630 Homo sapiens Low-density lipoprotein receptor-related protein 10 Proteins 0.000 description 4
- 101000721642 Homo sapiens Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha Proteins 0.000 description 4
- 101000628647 Homo sapiens Serine/threonine-protein kinase 24 Proteins 0.000 description 4
- 101000831940 Homo sapiens Stathmin Proteins 0.000 description 4
- 101000845269 Homo sapiens Transcription termination factor 1 Proteins 0.000 description 4
- 102100039285 Hyaluronidase-2 Human genes 0.000 description 4
- 108010041100 Integrin alpha6 Proteins 0.000 description 4
- 102000000426 Integrin alpha6 Human genes 0.000 description 4
- 229940123038 Integrin antagonist Drugs 0.000 description 4
- 101710148796 Intercellular adhesion molecule 5 Proteins 0.000 description 4
- 102000008070 Interferon-gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 4
- 102100021918 Low-density lipoprotein receptor-related protein 4 Human genes 0.000 description 4
- 238000002123 RNA extraction Methods 0.000 description 4
- 102100026764 Serine/threonine-protein kinase 24 Human genes 0.000 description 4
- 102100024237 Stathmin Human genes 0.000 description 4
- 102000000019 Sterol Esterase Human genes 0.000 description 4
- 108010055297 Sterol Esterase Proteins 0.000 description 4
- 108060008245 Thrombospondin Proteins 0.000 description 4
- 102000002938 Thrombospondin Human genes 0.000 description 4
- 108010023649 Tripartite Motif Proteins Proteins 0.000 description 4
- 102000011408 Tripartite Motif Proteins Human genes 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 238000013528 artificial neural network Methods 0.000 description 4
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 108010021208 connexin 31.1 Proteins 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229960003130 interferon gamma Drugs 0.000 description 4
- 238000012729 kappa analysis Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 201000002120 neuroendocrine carcinoma Diseases 0.000 description 4
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 4
- UUSZLLQJYRSZIS-LXNNNBEUSA-N plitidepsin Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-LXNNNBEUSA-N 0.000 description 4
- 229950008499 plitidepsin Drugs 0.000 description 4
- 108010049948 plitidepsin Proteins 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000010837 poor prognosis Methods 0.000 description 4
- 239000002987 primer (paints) Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000000391 smoking effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- BCOSEZGCLGPUSL-UHFFFAOYSA-N 2,3,3-trichloroprop-2-enoyl chloride Chemical compound ClC(Cl)=C(Cl)C(Cl)=O BCOSEZGCLGPUSL-UHFFFAOYSA-N 0.000 description 3
- JEPVUMTVFPQKQE-AAKCMJRZSA-N 2-[(1s,2s,3r,4s)-1,2,3,4,5-pentahydroxypentyl]-1,3-thiazolidine-4-carboxylic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C1NC(C(O)=O)CS1 JEPVUMTVFPQKQE-AAKCMJRZSA-N 0.000 description 3
- 102100032282 26S proteasome non-ATPase regulatory subunit 14 Human genes 0.000 description 3
- 101150039504 6 gene Proteins 0.000 description 3
- 102000010970 Connexin Human genes 0.000 description 3
- 108050001175 Connexin Proteins 0.000 description 3
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 3
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 3
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 3
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 3
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 3
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 3
- 101710131740 Docking protein 1 Proteins 0.000 description 3
- 102100030801 Elongation factor 1-alpha 1 Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 description 3
- 101000794587 Homo sapiens Cadherin-5 Proteins 0.000 description 3
- 101000943475 Homo sapiens Calcium and integrin-binding protein 1 Proteins 0.000 description 3
- 101000920078 Homo sapiens Elongation factor 1-alpha 1 Proteins 0.000 description 3
- 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 3
- 101001081606 Homo sapiens Islet cell autoantigen 1 Proteins 0.000 description 3
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 description 3
- 101000973177 Homo sapiens Nuclear factor interleukin-3-regulated protein Proteins 0.000 description 3
- 101001081953 Homo sapiens Phosphoribosylaminoimidazole carboxylase Proteins 0.000 description 3
- 101000788548 Homo sapiens Tubulin alpha-4A chain Proteins 0.000 description 3
- 101000830596 Homo sapiens Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 description 3
- 101000932850 Homo sapiens Voltage-dependent L-type calcium channel subunit beta-1 Proteins 0.000 description 3
- 102100026020 Hormone-sensitive lipase Human genes 0.000 description 3
- 102100032816 Integrin alpha-6 Human genes 0.000 description 3
- 102100027640 Islet cell autoantigen 1 Human genes 0.000 description 3
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 3
- 239000002137 L01XE24 - Ponatinib Substances 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 102100035304 Lymphotactin Human genes 0.000 description 3
- 101000686934 Mus musculus Prolactin-7D1 Proteins 0.000 description 3
- 102100022163 Nuclear factor interleukin-3-regulated protein Human genes 0.000 description 3
- 101700056750 PAK1 Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 102100025058 Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha Human genes 0.000 description 3
- 102100027330 Phosphoribosylaminoimidazole carboxylase Human genes 0.000 description 3
- 102100031206 Serine/threonine-protein kinase N1 Human genes 0.000 description 3
- 102000005465 Stathmin Human genes 0.000 description 3
- 108050003387 Stathmin Proteins 0.000 description 3
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 3
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 3
- 102100025239 Tubulin alpha-4A chain Human genes 0.000 description 3
- 102100031835 Unconventional myosin-VIIa Human genes 0.000 description 3
- 102100025568 Voltage-dependent L-type calcium channel subunit beta-1 Human genes 0.000 description 3
- 108010081667 aflibercept Proteins 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 229960003005 axitinib Drugs 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 238000007834 ligase chain reaction Methods 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 229960000639 pazopanib Drugs 0.000 description 3
- 229960003073 pirfenidone Drugs 0.000 description 3
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 3
- 229960002633 ramucirumab Drugs 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 239000002525 vasculotropin inhibitor Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 2
- NXUWTKIOMJSLSV-DEEZXRHXSA-N (2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]hexanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]propanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O NXUWTKIOMJSLSV-DEEZXRHXSA-N 0.000 description 2
- SPMVMDHWKHCIDT-UHFFFAOYSA-N 1-[2-chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-3-(5-methyl-3-isoxazolyl)urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC=1C=C(C)ON=1 SPMVMDHWKHCIDT-UHFFFAOYSA-N 0.000 description 2
- 101150019071 1C gene Proteins 0.000 description 2
- 101150033839 4 gene Proteins 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 2
- 101150003382 57 gene Proteins 0.000 description 2
- 108010082162 AZX 100 Proteins 0.000 description 2
- 102100034111 Activin receptor type-1 Human genes 0.000 description 2
- 102100026609 Aldehyde dehydrogenase family 3 member B1 Human genes 0.000 description 2
- 108010048154 Angiopoietin-1 Proteins 0.000 description 2
- 102100034594 Angiopoietin-1 Human genes 0.000 description 2
- 102100034608 Angiopoietin-2 Human genes 0.000 description 2
- 108010048036 Angiopoietin-2 Proteins 0.000 description 2
- 102400000068 Angiostatin Human genes 0.000 description 2
- 108010079709 Angiostatins Proteins 0.000 description 2
- 102100034613 Annexin A2 Human genes 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 241000045403 Astragalus propinquus Species 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 102100039339 Atrial natriuretic peptide receptor 1 Human genes 0.000 description 2
- 241000726103 Atta Species 0.000 description 2
- 101100208237 Bos taurus THBS2 gene Proteins 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
- 102100031168 CCN family member 2 Human genes 0.000 description 2
- 102100029968 Calreticulin Human genes 0.000 description 2
- 108090000549 Calreticulin Proteins 0.000 description 2
- 101800000626 Canstatin Proteins 0.000 description 2
- 102400000730 Canstatin Human genes 0.000 description 2
- 244000068645 Carya illinoensis Species 0.000 description 2
- 235000009025 Carya illinoensis Nutrition 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 102000000018 Chemokine CCL2 Human genes 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102100031186 Chromogranin-A Human genes 0.000 description 2
- 102000004360 Cofilin 1 Human genes 0.000 description 2
- 108090000996 Cofilin 1 Proteins 0.000 description 2
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 2
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 2
- 101710180995 Endonuclease 1 Proteins 0.000 description 2
- 108010079505 Endostatins Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 102000016970 Follistatin Human genes 0.000 description 2
- 108010014612 Follistatin Proteins 0.000 description 2
- 102100041002 Forkhead box protein H1 Human genes 0.000 description 2
- 241001200922 Gagata Species 0.000 description 2
- 229940126043 Galectin-3 inhibitor Drugs 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- OOFLZRMKTMLSMH-UHFFFAOYSA-N H4atta Chemical compound OC(=O)CN(CC(O)=O)CC1=CC=CC(C=2N=C(C=C(C=2)C=2C3=CC=CC=C3C=C3C=CC=CC3=2)C=2N=C(CN(CC(O)=O)CC(O)=O)C=CC=2)=N1 OOFLZRMKTMLSMH-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000676271 Homo sapiens 60S ribosomal protein L28 Proteins 0.000 description 2
- 101000717973 Homo sapiens Aldehyde dehydrogenase family 3 member B1 Proteins 0.000 description 2
- 101000695054 Homo sapiens Bombesin receptor subtype-3 Proteins 0.000 description 2
- 101000776612 Homo sapiens Cilia- and flagella-associated protein 73 Proteins 0.000 description 2
- 101000892840 Homo sapiens Forkhead box protein H1 Proteins 0.000 description 2
- 101000960337 Homo sapiens Intercellular adhesion molecule 5 Proteins 0.000 description 2
- 101001012669 Homo sapiens Melanoma inhibitory activity protein 2 Proteins 0.000 description 2
- 101000829958 Homo sapiens N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Proteins 0.000 description 2
- 101001116302 Homo sapiens Platelet endothelial cell adhesion molecule Proteins 0.000 description 2
- 101000634975 Homo sapiens Tripartite motif-containing protein 29 Proteins 0.000 description 2
- 108010020056 Hydrogenase Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 2
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 description 2
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 description 2
- 108010083015 MMI-0100 Proteins 0.000 description 2
- 102100029778 Melanoma inhibitory activity protein 2 Human genes 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 101100390562 Mus musculus Fen1 gene Proteins 0.000 description 2
- 102000003505 Myosin Human genes 0.000 description 2
- 108060008487 Myosin Proteins 0.000 description 2
- 102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 108010081689 Osteopontin Proteins 0.000 description 2
- 102000004264 Osteopontin Human genes 0.000 description 2
- 108010089484 PRM-151 Proteins 0.000 description 2
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 2
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 2
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 2
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 102000004211 Platelet factor 4 Human genes 0.000 description 2
- 108090000778 Platelet factor 4 Proteins 0.000 description 2
- 102100037869 Pleckstrin homology domain-containing family A member 6 Human genes 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 101100119953 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) fen gene Proteins 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 108050009586 Ribosomal protein L28 Proteins 0.000 description 2
- 108010005173 SERPIN-B5 Proteins 0.000 description 2
- 241001072909 Salvia Species 0.000 description 2
- 235000007154 Salvia chinensis Nutrition 0.000 description 2
- 240000006079 Schisandra chinensis Species 0.000 description 2
- 235000008422 Schisandra chinensis Nutrition 0.000 description 2
- 108010086019 Secretin Proteins 0.000 description 2
- 102100037505 Secretin Human genes 0.000 description 2
- 102100030333 Serpin B5 Human genes 0.000 description 2
- 102100024554 Tetranectin Human genes 0.000 description 2
- 108010057966 Thyroid Nuclear Factor 1 Proteins 0.000 description 2
- 102100037116 Transcription elongation factor 1 homolog Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 102100029519 Tripartite motif-containing protein 29 Human genes 0.000 description 2
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 2
- 229960004050 aminobenzoic acid Drugs 0.000 description 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960001292 cabozantinib Drugs 0.000 description 2
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 101150090195 cnb-1 gene Proteins 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 2
- 229960000766 danazol Drugs 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940017733 esbriet Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 2
- 238000010197 meta-analysis Methods 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229950003968 motesanib Drugs 0.000 description 2
- RAHBGWKEPAQNFF-UHFFFAOYSA-N motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 229960004708 noscapine Drugs 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 238000012567 pattern recognition method Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229960001131 ponatinib Drugs 0.000 description 2
- 238000011176 pooling Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 229960002101 secretin Drugs 0.000 description 2
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- RGYQPQARIQKJKH-UHFFFAOYSA-N setanaxib Chemical compound CN(C)C1=CC=CC(C2=C3C(=O)N(C=4C(=CC=CC=4)Cl)NC3=CC(=O)N2C)=C1 RGYQPQARIQKJKH-UHFFFAOYSA-N 0.000 description 2
- PEGQOIGYZLJMIB-UHFFFAOYSA-N setogepram Chemical compound CCCCCC1=CC=CC(CC(O)=O)=C1 PEGQOIGYZLJMIB-UHFFFAOYSA-N 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 150000003384 small molecules Chemical group 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229960000940 tivozanib Drugs 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 2
- 108010060757 vasostatin Proteins 0.000 description 2
- WCWUXEGQKLTGDX-LLVKDONJSA-N (2R)-1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-pyrrolo[2,1-f][1,2,4]triazinyl]oxy]-2-propanol Chemical compound C1=C2NC(C)=CC2=C(F)C(OC2=NC=NN3C=C(C(=C32)C)OC[C@H](O)C)=C1 WCWUXEGQKLTGDX-LLVKDONJSA-N 0.000 description 1
- KCOYQXZDFIIGCY-CZIZESTLSA-N (3e)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one Chemical compound C1CN(C)CCN1C1=CC=C(N\C(N2)=C/3C(=C4C(F)=CC=CC4=NC\3=O)N)C2=C1 KCOYQXZDFIIGCY-CZIZESTLSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- JKMPXGJJRMOELF-UHFFFAOYSA-N 1,3-thiazole-2,4,5-tricarboxylic acid Chemical compound OC(=O)C1=NC(C(O)=O)=C(C(O)=O)S1 JKMPXGJJRMOELF-UHFFFAOYSA-N 0.000 description 1
- LFKQSJNCVRGFCC-UHFFFAOYSA-N 1-(2,4-difluorophenyl)-3-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-fluorophenyl]urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1F)=CC=C1NC(=O)NC1=CC=C(F)C=C1F LFKQSJNCVRGFCC-UHFFFAOYSA-N 0.000 description 1
- YAHLWSGIQJATGG-UHFFFAOYSA-N 1-(4-chlorophenyl)cyclopropane-1-carboxylic acid Chemical compound C=1C=C(Cl)C=CC=1C1(C(=O)O)CC1 YAHLWSGIQJATGG-UHFFFAOYSA-N 0.000 description 1
- DEEOXSOLTLIWMG-UHFFFAOYSA-N 1-[2-[5-(2-methoxyethoxy)-1-benzimidazolyl]-8-quinolinyl]-4-piperidinamine Chemical compound C1=NC2=CC(OCCOC)=CC=C2N1C(N=C12)=CC=C1C=CC=C2N1CCC(N)CC1 DEEOXSOLTLIWMG-UHFFFAOYSA-N 0.000 description 1
- VPBYZLCHOKSGRX-UHFFFAOYSA-N 1-[2-chloro-4-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-propylurea Chemical compound C1=C(Cl)C(NC(=O)NCCC)=CC=C1OC1=NC=NC2=CC(OC)=C(OC)C=C12 VPBYZLCHOKSGRX-UHFFFAOYSA-N 0.000 description 1
- 101150000874 11 gene Proteins 0.000 description 1
- 101150097623 1B gene Proteins 0.000 description 1
- DOSMHBDKKKMIEF-UHFFFAOYSA-N 2-[3-(diethylamino)-6-diethylazaniumylidenexanthen-9-yl]-5-[3-[3-[4-(1-methylindol-3-yl)-2,5-dioxopyrrol-3-yl]indol-1-yl]propylsulfamoyl]benzenesulfonate Chemical compound C1=CC(=[N+](CC)CC)C=C2OC3=CC(N(CC)CC)=CC=C3C(C=3C(=CC(=CC=3)S(=O)(=O)NCCCN3C4=CC=CC=C4C(C=4C(NC(=O)C=4C=4C5=CC=CC=C5N(C)C=4)=O)=C3)S([O-])(=O)=O)=C21 DOSMHBDKKKMIEF-UHFFFAOYSA-N 0.000 description 1
- 108091071337 20 family Proteins 0.000 description 1
- NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(z)-(2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 description 1
- 102100039217 3-ketoacyl-CoA thiolase, peroxisomal Human genes 0.000 description 1
- QFCXANHHBCGMAS-UHFFFAOYSA-N 4-[[4-(4-chloroanilino)furo[2,3-d]pyridazin-7-yl]oxymethyl]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(COC=2C=3OC=CC=3C(NC=3C=CC(Cl)=CC=3)=NN=2)=C1 QFCXANHHBCGMAS-UHFFFAOYSA-N 0.000 description 1
- XXLPVQZYQCGXOV-UHFFFAOYSA-N 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one 2-hydroxypropanoic acid Chemical compound CC(O)C(O)=O.CC(O)C(O)=O.CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O XXLPVQZYQCGXOV-UHFFFAOYSA-N 0.000 description 1
- 101150095412 47 gene Proteins 0.000 description 1
- 101150096316 5 gene Proteins 0.000 description 1
- 101150047313 52 gene Proteins 0.000 description 1
- 102100040131 60S ribosomal protein L37 Human genes 0.000 description 1
- 102100036126 60S ribosomal protein L37a Human genes 0.000 description 1
- JGEBLDKNWBUGRZ-HXUWFJFHSA-N 9-[[[(2r)-1,4-dioxan-2-yl]methyl-methylsulfamoyl]amino]-2-(1-methylpyrazol-4-yl)-11-oxobenzo[1,2]cyclohepta[2,4-b]pyridine Chemical compound C=1C=C2C=CC3=NC=C(C4=CN(C)N=C4)C=C3C(=O)C2=CC=1NS(=O)(=O)N(C)C[C@@H]1COCCO1 JGEBLDKNWBUGRZ-HXUWFJFHSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 241001377084 Actites Species 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 102100026605 Aldehyde dehydrogenase, dimeric NADP-preferring Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 101710125943 Anthrax toxin receptor 1 Proteins 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 101100067703 Arabidopsis thaliana GALS3 gene Proteins 0.000 description 1
- 101710102163 Atrial natriuretic peptide receptor 1 Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 241000212384 Bifora Species 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 101100048443 Caenorhabditis elegans unc-3 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000011068 Cdc42 Human genes 0.000 description 1
- 108050001278 Cdc42 Proteins 0.000 description 1
- 208000013641 Cerebrofacial arteriovenous metameric syndrome Diseases 0.000 description 1
- 108010008978 Chemokine CXCL10 Proteins 0.000 description 1
- 102100024484 Codanin-1 Human genes 0.000 description 1
- 108010001463 Collagen Type XVIII Proteins 0.000 description 1
- 102000047200 Collagen Type XVIII Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- FCKYPQBAHLOOJQ-UHFFFAOYSA-N Cyclohexane-1,2-diaminetetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)C1CCCCC1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-UHFFFAOYSA-N 0.000 description 1
- 101710140553 Cytochrome b5 type B Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 101800001224 Disintegrin Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 229940123256 Fibroblast growth factor antagonist Drugs 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108010061414 Hepatocyte Nuclear Factor 1-beta Proteins 0.000 description 1
- 101710114425 Homeobox protein Nkx-2.1 Proteins 0.000 description 1
- 101001117935 Homo sapiens 60S ribosomal protein L15 Proteins 0.000 description 1
- 101000671735 Homo sapiens 60S ribosomal protein L37 Proteins 0.000 description 1
- 101001092424 Homo sapiens 60S ribosomal protein L37a Proteins 0.000 description 1
- 101100153048 Homo sapiens ACAA1 gene Proteins 0.000 description 1
- 101000961044 Homo sapiens Atrial natriuretic peptide receptor 1 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000980888 Homo sapiens Codanin-1 Proteins 0.000 description 1
- 101001036258 Homo sapiens Little elongation complex subunit 2 Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101000645296 Homo sapiens Metalloproteinase inhibitor 2 Proteins 0.000 description 1
- 101000831266 Homo sapiens Metalloproteinase inhibitor 4 Proteins 0.000 description 1
- 101000957437 Homo sapiens Mitochondrial carnitine/acylcarnitine carrier protein Proteins 0.000 description 1
- 101000869690 Homo sapiens Protein S100-A8 Proteins 0.000 description 1
- 101000728490 Homo sapiens Tether containing UBX domain for GLUT4 Proteins 0.000 description 1
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 description 1
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 1
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- 239000002139 L01XE22 - Masitinib Substances 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102100039420 Little elongation complex subunit 2 Human genes 0.000 description 1
- 108091077621 MAPRE family Proteins 0.000 description 1
- 102000042257 MAPRE family Human genes 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 1
- 102100024289 Metalloproteinase inhibitor 4 Human genes 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102100038738 Mitochondrial carnitine/acylcarnitine carrier protein Human genes 0.000 description 1
- 241001112258 Moca Species 0.000 description 1
- FOFDIMHVKGYHRU-UHFFFAOYSA-N N-(1,3-benzodioxol-5-ylmethyl)-4-(4-benzofuro[3,2-d]pyrimidinyl)-1-piperazinecarbothioamide Chemical compound C12=CC=CC=C2OC2=C1N=CN=C2N(CC1)CCN1C(=S)NCC1=CC=C(OCO2)C2=C1 FOFDIMHVKGYHRU-UHFFFAOYSA-N 0.000 description 1
- 102100032458 NADP-dependent malic enzyme, mitochondrial Human genes 0.000 description 1
- 101710087699 NADP-dependent malic enzyme, mitochondrial Proteins 0.000 description 1
- 102100028762 Neuropilin-1 Human genes 0.000 description 1
- 108090000772 Neuropilin-1 Proteins 0.000 description 1
- 101100202932 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) tsp-4 gene Proteins 0.000 description 1
- 101100202938 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) tsp-5 gene Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- NVRXTLZYXZNATH-UHFFFAOYSA-N PP121 Chemical compound N1=C(C=2C=C3C=CNC3=NC=2)C=2C(N)=NC=NC=2N1C1CCCC1 NVRXTLZYXZNATH-UHFFFAOYSA-N 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 102100032442 Protein S100-A8 Human genes 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 101001009851 Rattus norvegicus Guanylate cyclase 2G Proteins 0.000 description 1
- 101100208249 Rattus norvegicus Thbs4 gene Proteins 0.000 description 1
- 102100036240 Regulating synaptic membrane exocytosis protein 1 Human genes 0.000 description 1
- 101710108510 Regulating synaptic membrane exocytosis protein 1 Proteins 0.000 description 1
- 102400001051 Restin Human genes 0.000 description 1
- 108090000775 Ribosomal protein L2 Proteins 0.000 description 1
- 102000004208 Ribosomal protein L2 Human genes 0.000 description 1
- 101150071661 SLC25A20 gene Proteins 0.000 description 1
- 229940123578 Selectin antagonist Drugs 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101150040974 Set gene Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 101000930762 Sulfolobus acidocaldarius (strain ATCC 33909 / DSM 639 / JCM 8929 / NBRC 15157 / NCIMB 11770) Signal recognition particle receptor FtsY Proteins 0.000 description 1
- 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 1
- 108010046722 Thrombospondin 1 Proteins 0.000 description 1
- 101710088547 Thyroid transcription factor 1 Proteins 0.000 description 1
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 101710159262 Transcription termination factor 1 Proteins 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229950009545 amuvatinib Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003705 background correction Methods 0.000 description 1
- 238000013398 bayesian method Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 108010047153 bovine corneal protein 54 Proteins 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 101150102633 cact gene Proteins 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 229940056434 caprelsa Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 101150062912 cct3 gene Proteins 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 238000007635 classification algorithm Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229950009240 crenolanib Drugs 0.000 description 1
- DYNHJHQFHQTFTP-UHFFFAOYSA-N crenolanib Chemical compound C=1C=C2N(C=3N=C4C(N5CCC(N)CC5)=CC=CC4=CC=3)C=NC2=CC=1OCC1(C)COC1 DYNHJHQFHQTFTP-UHFFFAOYSA-N 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 108010038764 cytoplasmic linker protein 170 Proteins 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- NYDXNILOWQXUOF-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-UHFFFAOYSA-L 0.000 description 1
- 229950005778 dovitinib Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011985 exploratory data analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 230000004547 gene signature Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940049235 iclusig Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000012308 immunohistochemistry method Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940005319 inlyta Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960004655 masitinib Drugs 0.000 description 1
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000036438 mutation frequency Effects 0.000 description 1
- ONDPWWDPQDCQNJ-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;phosphoric acid Chemical compound OP(O)(O)=O.OP(O)(O)=O.C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 ONDPWWDPQDCQNJ-UHFFFAOYSA-N 0.000 description 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 229960004378 nintedanib Drugs 0.000 description 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229960003349 pemetrexed disodium Drugs 0.000 description 1
- 108010035774 phosphoribosylaminoimidazole carboxylase Proteins 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000004557 prognostic gene signature Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000007637 random forest analysis Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 108091008601 sVEGFR Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000002412 selectin antagonist Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- SIARJEKBADXQJG-LFZQUHGESA-N stearoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 SIARJEKBADXQJG-LFZQUHGESA-N 0.000 description 1
- 229940090374 stivarga Drugs 0.000 description 1
- 229940034785 sutent Drugs 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229950004186 telatinib Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 101150096625 unc-4 gene Proteins 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940069559 votrient Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229940036061 zaltrap Drugs 0.000 description 1
- 229960002760 ziv-aflibercept Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562147547P | 2015-04-14 | 2015-04-14 | |
| US62/147,547 | 2015-04-14 | ||
| PCT/US2016/027503 WO2016168446A1 (en) | 2015-04-14 | 2016-04-14 | Methods for typing of lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2982775A1 true CA2982775A1 (en) | 2016-10-20 |
Family
ID=57126370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2982775A Abandoned CA2982775A1 (en) | 2015-04-14 | 2016-04-14 | Methods for typing of lung cancer |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US20190203296A1 (enExample) |
| EP (1) | EP3283654A4 (enExample) |
| JP (1) | JP2018512160A (enExample) |
| CN (1) | CN107849613A (enExample) |
| CA (1) | CA2982775A1 (enExample) |
| WO (1) | WO2016168446A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3149209B1 (en) * | 2014-05-30 | 2021-02-17 | Genecentric Therapeutics, Inc. | Methods for typing of lung cancer |
| US11514289B1 (en) * | 2016-03-09 | 2022-11-29 | Freenome Holdings, Inc. | Generating machine learning models using genetic data |
| CA3024744A1 (en) | 2016-05-17 | 2017-11-23 | Genecentric Therapeutics, Inc. | Methods for subtyping of lung squamous cell carcinoma |
| US10934595B2 (en) | 2016-05-17 | 2021-03-02 | Genecentric Therapeutics, Inc. | Methods for subtyping of lung adenocarcinoma |
| CN109182526A (zh) * | 2018-10-10 | 2019-01-11 | 杭州翱锐生物科技有限公司 | 用于早期肝癌辅助诊断的试剂盒及其检测方法 |
| US20240336972A1 (en) * | 2021-07-30 | 2024-10-10 | Oregon Health & Science University | Methods for selecting melanoma patients for therapy and methods of reducing or preventing melanoma metastasis |
| CN116403648B (zh) * | 2023-06-06 | 2023-08-01 | 中国医学科学院肿瘤医院 | 一种基于多维分析建立的小细胞肺癌免疫新分型方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002343443A1 (en) * | 2001-09-28 | 2003-04-14 | Whitehead Institute For Biomedical Research | Classification of lung carcinomas using gene expression analysis |
| TW200413725A (en) * | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
| US20060024692A1 (en) * | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
| WO2008151110A2 (en) * | 2007-06-01 | 2008-12-11 | The University Of North Carolina At Chapel Hill | Molecular diagnosis and typing of lung cancer variants |
| CN101509035A (zh) * | 2008-09-05 | 2009-08-19 | 中国人民解放军总医院 | 肺癌分型的基因序列及其应用 |
| EP3149209B1 (en) * | 2014-05-30 | 2021-02-17 | Genecentric Therapeutics, Inc. | Methods for typing of lung cancer |
-
2016
- 2016-04-14 CN CN201680034117.9A patent/CN107849613A/zh active Pending
- 2016-04-14 EP EP16780736.1A patent/EP3283654A4/en not_active Withdrawn
- 2016-04-14 US US15/566,363 patent/US20190203296A1/en not_active Abandoned
- 2016-04-14 CA CA2982775A patent/CA2982775A1/en not_active Abandoned
- 2016-04-14 WO PCT/US2016/027503 patent/WO2016168446A1/en not_active Ceased
- 2016-04-14 JP JP2017553970A patent/JP2018512160A/ja active Pending
-
2021
- 2021-01-08 US US17/144,644 patent/US20210147948A1/en not_active Abandoned
- 2021-09-10 US US17/471,716 patent/US20220002820A1/en not_active Abandoned
-
2022
- 2022-04-21 US US17/725,936 patent/US20220243283A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20220002820A1 (en) | 2022-01-06 |
| US20190203296A1 (en) | 2019-07-04 |
| EP3283654A4 (en) | 2018-12-12 |
| WO2016168446A1 (en) | 2016-10-20 |
| US20220243283A1 (en) | 2022-08-04 |
| JP2018512160A (ja) | 2018-05-17 |
| CN107849613A (zh) | 2018-03-27 |
| US20210147948A1 (en) | 2021-05-20 |
| EP3283654A1 (en) | 2018-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7241353B2 (ja) | 肺腺癌のサブタイピングのための方法 | |
| US20220243283A1 (en) | Methods for typing of lung cancer | |
| US10829819B2 (en) | Methods for typing of lung cancer | |
| US11851715B2 (en) | Detecting cancer cell of origin | |
| EP3458611A1 (en) | Methods for subtyping of lung squamous cell carcinoma | |
| WO2019032525A1 (en) | PROCESS FOR SUBTYPING EPIDERMOID CARCINOMA OF HEAD AND NECK | |
| US11739386B2 (en) | Methods for determining response to PARP inhibitors | |
| US12195805B2 (en) | Methods for subtyping of bladder cancer | |
| US20240182984A1 (en) | Methods for assessing proliferation and anti-folate therapeutic response | |
| WO2021262696A2 (en) | Methods for selecting and treating cancer with fgfr3 inhibitors | |
| WO2025259592A1 (en) | Therapeutic predictive response signatures and uses thereof in cancer patients | |
| WO2023164595A2 (en) | Methods for subtyping and treatment of head and neck squamous cell carcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20220705 |
|
| FZDE | Discontinued |
Effective date: 20220705 |